Cullinan Therapeutics, Inc. (CGEM)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
CGEM price, last 12 months
Key stats
- Previous close
- $15.44
- Open
- $15.62
- Day range
- $14.67 – $15.62
- 52-week range
- $5.68 – $23.19
- Volume
- 1.7M
- Avg volume (20 days)
- 1.2M
- Market cap
- $953.1M
Performance
Technicals and fundamentals
About Cullinan Therapeutics, Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $953.1M